|
|
|
|
|
16.11.26 - 22:12
|
Insight Molecular Diagnostics Announces Proposed Public Offering (GlobeNewswire EN)
|
|
|
NASHVILLE, Tenn., Nov. 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc. (Nasdaq: IMDX) (“iMDx,” “we,” “us,” “our,” or the “Company”) today announced that it has commenced an underwritten public offering of shares of its common stock, or, in lieu of common stock to certain investors, pre-funded warrants to purchase shares of its common stock. In addition, the Company intends to grant the underwriter a 30-day option to purchase up to an additional 15% of the total number of shares of common stock offered in the public offering (including shares issuable upon exercise of the pre-funded warrants). The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the offering....
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
16.06.26 - 22:12
|
Favorable Head-to-Head Data on iMDx′s GraftAssure with Competing NGS Assay Published in Clinical Chemistry (GlobeNewswire EN)
|
|
|
NASHVILLE, Tenn., June 16, 2026 (GLOBE NEWSWIRE) -- Insight Molecular Diagnostics Inc., (Nasdaq: IMDX) ("iMDx") today announced the online publication of a favorable article in Clinical Chemistry, the premier, peer-reviewed scientific publication of the Association for Diagnostics & Laboratory Medicine. The article highlights the concordant performance between iMDx's digital-PCR-based flagship transplant monitoring test, GraftAssure™, and a competing next-generation-sequencing-based assay kit that is sold outside of the U.S....
|
|
|
|
|
|
|
|
|
|
|
|
|
|